Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | BRD4 | O60885 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19210848 | 0.93 | KDM4E (0.70) | ADRA1DSLC6A4KDM4EATMBRD4 | |
| SCHEMBL14306777 | 0.88 | ADRA1D (0.80) | ADRA1DSLC6A4KDM4EATMCYP2D6 | |
| SCHEMBL4475225 | 0.85 | ADRA1D (0.67) | ADRA1DSLC6A4KDM4EATMBRD4 | |
| SCHEMBL27467624 | 0.85 | ADRA1D (0.77) | ADRA1DSLC6A4CYP2D6 | |
| SCHEMBL27482702 | 0.85 | ADRA1D (0.63) | ADRA1DSLC6A4KDM4EATMBRD4 | |
| SCHEMBL27897369 | 0.85 | KDM4E (0.66) | ADRA1DSLC6A4KDM4EATMBRD4 | |
| SCHEMBL14282282 | 0.84 | ADRA1D (0.66) | ADRA1DSLC6A4KDM4EATMBRD4 | |
| Hydrochloric Acid SCHEMBL7259157 | 0.84 | ADRA1D (0.90) | ADRA1DSLC6A4CYP2D6 | |
| SCHEMBL14280709 | 0.84 | ADRA1D (0.80) | ADRA1DSLC6A4CYP2D6 | |
| SCHEMBL30415306 | 0.83 | KDM4E (0.83) | ADRA1DKDM4EATMBRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | ADRA1D 71/4885SLC6A4 3/4885KDM4E 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.